The Japanese pharmaceutical company Daiichi-Sankyo is investing one billion euros to develop and produce its new generation of cancer drugs in Pfaffenhofen, Upper Bavaria. The company announced this on Friday.
This involves so-called antibody-drug conjugates (ADCs). To put it simply, these are chemotherapies that work directly in the cancer cell. The products are revolutionary for patients and the market potential is huge.
According to estimates by market research firm Markets and Markets, global sales of ADCs will double from almost $10 billion last year to nearly $20 billion in 2028.
Daiichi-Sankyo, together with the British pharmaceutical company Astra-Zeneca, sells the currently fastest-growing ADC Enhertu, which is used in the treatment of inoperable breast cancer, but now also for the treatment of lung cancer and stomach cancer.
